| Chemical class | Mechanism of action | Details |
New drugs | | | |
Bedaquiline (TMC-207) | Diarylquinoline | Inhibits mycobacterial ATP synthase | Clinical development (phase III) Approved by US Food and Drug Administration and European Medicines Agency Included in WHO group 5 drugs |
Delamanid (OPC-67683) | Nitroimidazole | Inhibits mycolic acid cell wall | Clinical development (phase III) Approved by European Medicines Agency Included in WHO Group 5 drugs |
Sutezolid (PNU-100480) | Oxazolidinone | Inhibits microbial protein synthesis by blocking 50S ribosomal subunit | Clinical development (phase II) |
AZD-5847 | Oxazolidinone | Inhibits microbial protein synthesis by blocking 50S ribosomal subunit | Clinical development (phase II) |
PA-824 | Nitroimidazole | Inhibits cell wall synthesis | Clinical development (phase IIb) |
SQ-109 | Ethylenediamine | Inhibits cell wall synthesis | Clinical development (phase II) |
Drugs originally developed with different indications than TB | | | |
Clofazimine | Riminophenazine | Binds to mycobacterial DNA (disrupting the cell cycle) and to bacterial potassium transporters, thereby inhibiting their function | Clinical development (phase II) |
Included in WHO Group 5 drugs |
Linezolid | Oxazolidinone | Inhibits microbial protein synthesis by blocking 50S ribosomal subunit | Clinical development (phase II) Included in WHO Group 5 drugs |
Moxifloxacin | Fluoroquinolone | Inhibits DNA gyrase | Clinical development (phase III) Included in WHO Group 3 drugs |